10x Genomics Shares Tumble on Fear Over Cuts to NIH
A Wednesday night earnings report left big questions about how the spending reductions would affect the company.
StockStory.org on MSN1d
Why 10x Genomics (TXG) Shares Are Falling Today
Shares of biotech company 10x Genomics (NASDAQ:TXG) fell 8.5% in the pre-market session after the company reported ...
10x Genomics (TXG) Receives a Buy from Morgan Stanley
Morgan Stanley analyst Tejas Savant maintained a Buy rating on 10x Genomics (TXG – Research Report) today and set a price target of $26.00. The ...
Hosted on MSN20h
Leerink Partners Downgrades 10x Genomics (TXG)
Fintel reports that on February 13, 2025, Leerink Partners downgraded their outlook for 10x Genomics (NasdaqGS:TXG) from ...
Life Science Company 10x Genomics Struggles With Profitability, Analyst Says 2025 Guidance Bakes In NIH Funding Uncertainties
On Wednesday, 10x Genomics Inc (NASDAQ:TXG) reported a fourth-quarter EPS loss of $(0.40), missing the consensus estimate of ...
10x Genomics price target lowered to $18 from $21 at Stifel
Stifel lowered the firm’s price target on 10x Genomics (TXG) to $18 from $21 and keeps a Buy rating on the shares. The funding environment ...
10x Genomics sees robust growth across platforms in Q4 2023
CEO Serge Saxonov highlighted strong growth across platforms, with total revenue for Q4 2023 reaching $184 million, an 18% increase year-over-year. Spatial products contributed significantly, with ...
10x Genomics Inc (TXG) Q4 2024 Earnings Call Highlights: Navigating Challenges with Strategic ...
Despite a challenging macro environment, 10x Genomics Inc (TXG) focuses on product innovation and biopharma expansion to ...